Biocon sells 80 lacs equity shares of Syngene International for Rs 686 crores
Bangalore: Biocon has sold Eighty Lacs equity shares of Syngene International Limited for Rs. 686 crores. The transacted value is the gross amount on the exchange and is subject to statutory levies, brokerage etc.
The shares were sold in the open market through a block deal mechanism on December 10, 2024
Post the transaction, the shareholding of the Company in Syngene shall stand at 52.46%.
"None of the buyers belong to the Promoter/ Promoter group/ group companies," the Company stated in a BSE filing.
Medical Dialogues team also reported that Biocon Biologics Limited, a subsidiary of Biocon Limited, has once again been recognized as an Asia IP Elite for 2024 by IAM (Intellectual Asset Management), a Intellectual Property (IP) publication. This is the eighth consecutive year for Biocon and subsequently its subsidiary Biocon Biologics to make it to this prestigious list. This prestigious accolade is awarded to a select group of Asia-based organisations that have demonstrated exceptional IP value creation and are considered leaders in the region.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.